ערך בספרים למניה: revivapharma.com (RVPH)

The book value per share chart demonstrates the actual asset base of Reviva Pharmaceuticals (RVPH), with 1.47 serving as the current parameter value. Reviva Pharmaceuticals (RVPH) faces significant binary risk due to its focus on a single schizophrenia drug. Production is outsourced to external CDMO partners, which eliminates technical failures. The business model is scalable: patenting the development will ensure global profits with low costs.

Net asset value assessment is critical for Reviva Pharmaceuticals (RVPH), a biotechnology sector company developing innovative drugs for the therapy of psychiatric disorders. This metric is calculated as the difference between all company assets and liabilities divided by the number of shares, allowing investors to determine the intrinsic value of the security and assess risks via a chart of the historical book value per share.